Immunoliposomes for cancer therapy

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 1, 2006, Pages 39-45

  Kontermann, Roland E ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

Drug delivery; Fab' fragment; Liposomes; Single chain Fv; Sterically stabilized immunoliposomes; Targeting

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CHOLESTEROL; CYTARABINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; INDINAVIR; LIPOSOME; MACROGOL 2000; METHOTREXATE; NAVELBINE; NSC 701315; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA; SPHINGOMYELIN; TRASTUZUMAB; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CYTOTOXICITY; DEATH; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RETENTION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; IMMUNOGENICITY; NEUROBLASTOMA; NONHUMAN; REVIEW; RNA INTERFERENCE; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LIPOSOMES; NEOPLASMS;

EID: 32544452539     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. 2 to vesicle surface. Science (1980) 210(4469):539-541.
2. Leserman LD, Barbet J, Kourilsky F, Weinstein JN: Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature (1980) 288(5791):602-604.
3. Park YS: Tumor-directed targeting of liposomes. Biosci Rep (2002) 22(2):267-281.
4. Sapra P, Allen TM: Ligand-targeted liposomal anticancer drugs. Prog Lipid Res (2003) 42(5):439-462.
5. Park JW, Benz CC, Martin FJ: Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol (2004) 31(6 Suppl 13):196-205.
6. Allen TM, Cullis PR: Drug delivery systems: Entering the mainstream. Science (2004) 303(5665):1818-1822.
7. Schnyder A, Huwyler J: Drug transport to brain with targeted liposomes. NeuroRx (2005) 2(1):99-107.
8. Park JW, Hong K, Carter P, Asgari H, Guo LY, Kelle GA, Wirth C, Shalaby R, Kotts C, Wood WI, Papahadjopoulos D, Benz CC: Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA (1995) 92(5):1327-1331.
9. Bendas G, Krause A, Bakowsky U, Vogel J, Rothe U: Targetability of novel immunoliposomes prepared by a new antibody conjugation technique. Int J Pharm (1999) 181(1):79-93.
10. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM: Attachment of antibodies to sterically stabilized liposomes: Evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta (1995) 1239(2):133-144.
11. Harding JA, Engbers CM, Newman MS, Goldstein NI, Zalipsky S: Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta (1997) 1327(2):181-192.
12. Bendas G, Rothe U, Scherphof GL, Kamps JA: The influence of repeated injections on pharmacokinetics and biodistribution of different types of sterically stabilized immunoliposomes. Biochim Biophys Acta (2003) 1609(1):63-70.
13. Koning GA, Morselt HW, Gorter A, Allen TM, Zalipsky S, Scherphof GL, Kamps JA: Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison. Pharm Res (2003) 20(8):1249-1257.
14. Nobs L, Buchegger F, Gumy R, Allémann E: Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci (2004) 93(8):1980-1992.
15. Gagné JF, Desormeaux A, Perron S, Tremblay MJ, Bergeron MG: Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim Biophys Acta (2002) 1558(2):198-210.
16. Pastorino F, Brignole C, Marimpietri D, Sapra P, Hoase EH, Allen TM, Ponzoni M: Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res (2003) 63(1):86-92.
17. Hoogenboom HR: Selecting and screening recombinant antibody libraries. Nat Biotechnol (2005) 23(9):1105-1116.
18. Lonberg N: Human antibodies from transgenic animals. Nat Biotechnol (2005) 23(9):1117-1125.
19. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC: Tumor targeting using anti-HER2 immunoliposomes. J Control Release (2001) 74(1-3):95-113.
20. Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD: Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta (2002) 1591(1-3):109-118.
21. Marty C, Odermatt B, Schott H, Neri D, Ballmer-Hofer K, Klemenz R, Schwendener RA: Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br J Cancer (2002) 87(1):106-112.
22. Völkel T, Hölig P, Merdan T, Müller R, Kontermann RE: Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta (2004) 1663(1-2):158-166.
23. Marty C, Langer-Machova Z, Sigrist S, Schott H, Schwendener RA, Ballmer-Hofer K: Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Cancer Lett (2005):doi:10.1016/j.canlet.2005.04.029.
24. Iden DL, Allen TM: In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta (2001) 1513(2):207-216.
25. 6-Cys scFv. Protein Exp Purif (2005) 39(2):1199-1208.
26. Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K et al: Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prop (2005) 21(1):205-220.
27. de Kruif J, Storm G, van Bloois L, Logtenberg T: Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. FEBS Lett (1996) 399(3):232-236.
28. Rüger R, Müller D, Fahr A, Kontermann RE: Generation of immunoliposomes using recombinant single-chain Fv fragments bound to NI-NTA-liposomes. J Drug Targeting (2005) 13(7):399-406.
29. Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, Kirpotin DB: Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prop (2005) 21(1):221-232.
30. Holliger P, Hudson PJ: Engineered antibody fragments and the rise of single domains. Nat Biotechnol (2005) 23(9):1126-1136.
31. Binz HK, Amstutz P, Plückthun A: Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol (2005) 23(10):1257-1268.
32. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC: Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin Cancer Res (2002) 8(4):1172-1181.
33. Sapra P, Allen TM: Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res (2002) 62(24):7190-7194.
34. Allen TM, Mumbengegwi DR, Charrois GJ: Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res (2005) 11(9):3567-3573.
35. Sapra P, Allen TM: Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res (2004) 10(7):2530-2537.
36. Sapra P, Moase EH, Ma J, Allen TM: Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal dozorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin Cancer Res (2004) 10(3):1100-1111.
37. Hosokawa S, Tagawa T, Niki H, Hirakawa Y, Nohga K, Nagaike K: Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner. Br J Cancer (2003) 89(8):1545-1551.
38. Moase EH, Qi W, Ishida T, Gabos Z, Longenecker BM, Zimmermann GL, Ding L, Krantz M, Allen TM: Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim Biophys Acta (2001) 1510(1-2):43-55.
39. Everts M, Koning GA, Kok RJ, Ásgeirsdóttir SA, Vestweber D, Meijer DKF, Storm G, Molema G: In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. Pharm Res (2003) 20(1):64-72.
40. Rubio Demirovic, A, Marty C, Console S, Zeisberger SM, Ruch C, Jaussi R, Schwendener RA, Ballmer-Hofer K: Targeting human cancer cells with VEGF receptor-2-directed liposomes. Oncol Rep (2005) 13(2):319-324.
41. Voinea M, Manduteanu I, Dragomir E, Capraru M, Simionescu M: Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells - a potent tool for specific drug delivery. Pharm Res (2005) 22(11):1906-1917.
42. Brignole C, Marimpietri D, Pagnan G, Di Paolo D, Zancolli M, Pistoia V, Ponzoni M, Pastorino F: Neuroblastoma targeting by c-Myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: Immune cell-mediated anti-tumor activities. Cancer Lett (2005) 228(1-2):181-186.
43. Fonseca MJ, Jagtenberg JC, Haisma HJ, Storm G: Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: Comparison with the corresponding antibody-enzyme conjugate. Pharm Res (2003) 20(3):423-328.
44. Mulder WJ, Strijkers GJ, Griffioen AW, van Bloois L, Molema G, Storm G, Koning GA, Nicolay K: A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem (2004) 15(4):799-806.
45. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 65(15):6910-6918.
46. Yano J, Hirabayashi K, Nakagawa S, Yamaguchi T, Nogawa M, Kashimori I, Naito H, Kitagawa H, Ishiyama K, Ohgi T, Irimura T: Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res (2004) 10(22):7721-7726.
47. Pal A, Ahmad A, Khan S, Sakabe I, Zhang C, Kasid UN, Ahmad I: Systemic delivery of Raf siRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol (2005) 26(4):1087-1091.
48. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM: Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res (2004) 10(11):3667-3677.
49. Lee CH, Hsiao M, Tseng YL, Chang FH: Enhanced gene delivery to HER-2-overexpressing breast cancer cells by modified immunolipoplexes conjugated with anti-HER-2 antibody. J Biomed Sci (2003) 10(3):337-344.
50. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Par JW: Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res (2003) 63(12):3154-3161.
51. Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC: Anti-HERZ immunoliposomes for targeted therapy of huma tumors. Cancer Lett (1997) 118(2):153-160.
52. Maruyama K, Takahashi N, Tagawa T, Nagaike K, Iwatsuru M: Immunoliposomes beating polyethyleneglycol-coupled Fab' fragment show prolonged circuation time and high extravasation into targeted solid tumors in vivo. FEBS Lett (1997) 413(1):177-180.
53. Shahinian S, Silvius JR: A novel strategy affords high-yield coupling of antibody Fab' fragments to liposomes. Biochim Biophys Acta (1995) 1239(2):157-167.
54. Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ, Cruz I, Xiang LM, Pirollo KF, Chang EH: Systemic tumor targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther (2002) 1(5):337-346.